-
1
-
-
34548283459
-
Are oncoantigens suitable targets for anti-tumour therapy?
-
DOI 10.1038/nrc2208, PII NRC2208
-
Cavallo F, Calogero RA, Forni G (2007) Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 7(9):707-713. doi:10.1038/nrc2208 (Pubitemid 47327413)
-
(2007)
Nature Reviews Cancer
, vol.7
, Issue.9
, pp. 707-713
-
-
Cavallo, F.1
Calogero, R.A.2
Forni, G.3
-
2
-
-
0035163903
-
Combined allogeneic tumor cell vaccination and systematic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
-
DOI 10.1084/jem.194.9.1195
-
Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL (2001) Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194(9):1195-1205 (Pubitemid 33055039)
-
(2001)
Journal of Experimental Medicine
, vol.194
, Issue.9
, pp. 1195-1205
-
-
Nanni, P.1
Nicoletti, G.2
De Giovanni, C.3
Landuzzi, L.4
Di Carlo, E.5
Cavallo, F.6
Pupa, S.M.7
Rossi, I.8
Colombo, M.P.9
Ricci, C.10
Astolfi, A.11
Musiani, P.12
Forni, G.13
Lollini, P.-L.14
-
3
-
-
77950801051
-
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins
-
doi:10.1158/0008-5472.CAN-09-2548
-
Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F (2010) A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 70(7):2604-2612. doi:10.1158/0008-5472. CAN-09-2548
-
(2010)
Cancer Res
, vol.70
, Issue.7
, pp. 2604-2612
-
-
Quaglino, E.1
Mastini, C.2
Amici, A.3
Marchini, C.4
Iezzi, M.5
Lanzardo, S.6
De Giovanni, C.7
Montani, M.8
Lollini, P.L.9
Masucci, G.10
Forni, G.11
Cavallo, F.12
-
4
-
-
33646786773
-
Vaccination for treatment and prevention of cancer in animal models
-
DOI 10.1016/S0065-2776(06)90005-4, PII S0065277606900054
-
Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ (2006) Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 90:175-213. doi:10.1016/S0065-2776(06)90005-4 (Pubitemid 43765801)
-
(2006)
Advances in Immunology
, vol.90
, pp. 175-213
-
-
Cavallo, F.1
Offringa, R.2
Van Der Burg, S.H.3
Forni, G.4
Melief, C.J.M.5
-
5
-
-
44949166624
-
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
-
DOI 10.1038/nm1769, PII NM1769
-
Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, Inghirami G (2008) The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14(6):676-680. doi:10.1038/nm1769 (Pubitemid 351809545)
-
(2008)
Nature Medicine
, vol.14
, Issue.6
, pp. 676-680
-
-
Chiarle, R.1
Martinengo, C.2
Mastini, C.3
Ambrogio, C.4
D'Escamard, V.5
Forni, G.6
Inghirami, G.7
-
6
-
-
0037303197
-
Cancer immunoprevention: Tracking down persistent tumor antigens
-
DOI 10.1016/S1471-4906(02)00030-3, PII S1471490602000303
-
Lollini PL, Forni G (2003) Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 24(2):62-66. doi:S1471490602000303 (Pubitemid 36120640)
-
(2003)
Trends in Immunology
, vol.24
, Issue.2
, pp. 62-66
-
-
Lollini, P.-L.1
Forni, G.2
-
7
-
-
33644534148
-
Vaccines for tumour prevention
-
DOI 10.1038/nrc1815, PII N1815
-
Lollini PL, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6(3):204-216. doi:10.1038/nrc1815 (Pubitemid 43292564)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.3
, pp. 204-216
-
-
Lollini, P.-L.1
Cavallo, F.2
Nanni, P.3
Forni, G.4
-
8
-
-
33745155742
-
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth
-
DOI 10.1073/pnas.0603110103
-
Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmaki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R (2006) A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA 103(24):9208-9213. doi:10.1073/pnas.0603110103 (Pubitemid 43902557)
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.24
, pp. 9208-9213
-
-
Holmgren, L.1
Ambrosino, E.2
Birot, O.3
Tullus, C.4
Veitonmaki, N.5
Levchenko, T.6
Carlson, L.-M.7
Musiani, P.8
Iezzi, M.9
Curcio, C.10
Forni, G.11
Cavallo, F.12
Kiessling, R.13
-
9
-
-
0030576517
-
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
-
DOI 10.1016/S0092-8674(00)80108-7
-
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364. doi:S0092-8674(00) 80108-710 (Pubitemid 26272076)
-
(1996)
Cell
, vol.86
, Issue.3
, pp. 353-364
-
-
Hanahan, D.1
Folkman, J.2
-
10
-
-
0028951043
-
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
-
Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1(2):149-153
-
(1995)
Nat Med
, vol.1
, Issue.2
, pp. 149-153
-
-
Holmgren, L.1
O'reilly, M.S.2
Folkman, J.3
-
11
-
-
0035911953
-
Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation
-
DOI 10.1083/jcb.152.6.1247
-
Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L (2001) Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152(6):1247-1254 (Pubitemid 34280181)
-
(2001)
Journal of Cell Biology
, vol.152
, Issue.6
, pp. 1247-1254
-
-
Troyanovsky, B.1
Levchenko, T.2
Mansson, G.3
Matvijenko, O.4
Holmgren, L.5
-
12
-
-
0037130937
-
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains
-
DOI 10.1016/S0378-1119(02)00928-9, PII S0378111902009289
-
Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, Holmgren L (2002) Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 298(1):69-77. doi:S0378111902009289 (Pubitemid 35284264)
-
(2002)
Gene
, vol.298
, Issue.1
, pp. 69-77
-
-
Bratt, A.1
Wilson, W.J.2
Troyanovsky, B.3
Aase, K.4
Kessler, R.5
Meir, E.G.V.6
Holmgren, L.7
-
13
-
-
1442332677
-
Angiomotin expression promotes hemangioendothelioma invasion
-
DOI 10.1038/sj.onc.1207264
-
Levchenko T, Bratt A, Arbiser JL, Holmgren L (2004) Angiomotin expression promotes hemangioendothelioma invasion. Oncogene 23(7):1469-1473. doi:10.1038/sj.onc.1207264 (Pubitemid 38406842)
-
(2004)
Oncogene
, vol.23
, Issue.7
, pp. 1469-1473
-
-
Levchenko, T.1
Bratt, A.2
Arbiser, J.L.3
Holmgren, L.4
-
14
-
-
39149088327
-
Differential roles of p80-and p130-angiomotin in the switch between migration and stabilization of endothelial cells
-
doi:10.1016/j.bbamcr.2007.11.018
-
Ernkvist M, Birot O, Sinha I, Veitonmaki N, Nystrom S, Aase K, Holmgren L (2008) Differential roles of p80-and p130-angiomotin in the switch between migration and stabilization of endothelial cells. Biochim Biophys Acta 1783(3):429-437. doi:10.1016/j.bbamcr.2007.11.018
-
(2008)
Biochim Biophys Acta
, vol.1783
, Issue.3
, pp. 429-437
-
-
Ernkvist, M.1
Birot, O.2
Sinha, I.3
Veitonmaki, N.4
Nystrom, S.5
Aase, K.6
Holmgren, L.7
-
15
-
-
0032479871
-
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice
-
DOI 10.1084/jem.188.3.589
-
Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188(3):589-596 (Pubitemid 28369147)
-
(1998)
Journal of Experimental Medicine
, vol.188
, Issue.3
, pp. 589-596
-
-
Boggio, K.1
Nicoletti, G.2
Di Carlo, E.3
Cavallo, F.4
Landuzzi, L.5
Melani, C.6
Giovarelli, M.7
Rossi, I.8
Nanni, P.9
De Giovanni, C.10
Bouchard, P.11
Wolf, S.12
Modesti, A.13
Musiani, P.14
Lollini, P.L.15
Colombo, M.P.16
Forni, G.17
-
16
-
-
0034326620
-
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
-
Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165(9):5133-5142
-
(2000)
J Immunol
, vol.165
, Issue.9
, pp. 5133-5142
-
-
Rovero, S.1
Amici, A.2
Carlo, E.D.3
Bei, R.4
Nanni, P.5
Quaglino, E.6
Porcedda, P.7
Boggio, K.8
Smorlesi, A.9
Lollini, P.L.10
Landuzzi, L.11
Colombo, M.P.12
Giovarelli, M.13
Musiani, P.14
Forni, G.15
-
17
-
-
33646250667
-
P130-angiomotin associates to actin and controls endothelial cell shape
-
doi:10.1111/j.1742-4658.2006.05216.x
-
Ernkvist M, Aase K, Ukomadu C, Wohlschlegel J, Blackman R, Veitonmaki N, Bratt A, Dutta A, Holmgren L (2006) p130-angiomotin associates to actin and controls endothelial cell shape. FEBS J 273(9):2000-2011. doi:10.1111/j.1742- 4658.2006.05216.x
-
(2006)
FEBS J
, vol.273
, Issue.9
, pp. 2000-2011
-
-
Ernkvist, M.1
Aase, K.2
Ukomadu, C.3
Wohlschlegel, J.4
Blackman, R.5
Veitonmaki, N.6
Bratt, A.7
Dutta, A.8
Holmgren, L.9
-
18
-
-
0036337222
-
Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI
-
DOI 10.1016/S1076-6332(03)80273-8
-
Cavagna FM, Lorusso V, Anelli PL, Maggioni F, de Haen C (2002) Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. Acad Radiol 9(Suppl 2):S491-S494 (Pubitemid 34857764)
-
(2002)
Academic Radiology
, vol.9
, Issue.SUPPL. 2
-
-
Cavagna, F.M.1
Lorusso, V.2
Anelli, P.L.3
Maggioni, F.4
De Haen, C.5
-
19
-
-
3042716652
-
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time
-
DOI 10.1002/jmri.20061
-
Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM (2004) Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging 20(1):122-128. doi:10.1002/jmri.20061 (Pubitemid 38857525)
-
(2004)
Journal of Magnetic Resonance Imaging
, vol.20
, Issue.1
, pp. 122-128
-
-
Medved, M.1
Karczmar, G.2
Yang, C.3
Dignam, J.4
Gajewski, T.F.5
Kindler, H.6
Vokes, E.7
MacEneany, P.8
Mitchell, M.T.9
Stadler, W.M.10
-
20
-
-
4043147286
-
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice
-
DOI 10.1158/0008-5472.CAN-03-2962
-
Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64(8):2858-2864 (Pubitemid 38500626)
-
(2004)
Cancer Research
, vol.64
, Issue.8
, pp. 2858-2864
-
-
Quaglino, E.1
Iezzi, M.2
Mastini, C.3
Amici, A.4
Pericle, F.5
Di Carlo, E.6
Pupa, S.M.7
De Giovanni, C.8
Spadaro, M.9
Curcio, C.10
Lollini, P.L.11
Musiani, P.12
Forni, G.13
Cavallo, F.14
-
21
-
-
0035300530
-
A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia
-
Cifaldi L, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini PL, Wolf S, Boggio K, Forni G, Cavallo F (2001) A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 61(7):2809-2812 (Pubitemid 32691915)
-
(2001)
Cancer Research
, vol.61
, Issue.7
, pp. 2809-2812
-
-
Cifaldi, L.1
Quaglino, E.2
Di Carlo, E.3
Musiani, P.4
Spadaro, M.5
Lollini, P.L.6
Wolf, S.7
Boggio, K.8
Forni, G.9
Cavallo, F.10
-
22
-
-
77953438206
-
Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent lowavidity T cells: Potential and limits of its therapeutic efficacy
-
doi:10.4049/jimmunol.0901215
-
Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolo C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F (2010) Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent lowavidity T cells: potential and limits of its therapeutic efficacy. J Immunol 184(11):6124-6132. doi:10.4049/jimmunol.0901215
-
(2010)
J Immunol
, vol.184
, Issue.11
, pp. 6124-6132
-
-
Rolla, S.1
Ria, F.2
Occhipinti, S.3
Di Sante, G.4
Iezzi, M.5
Spadaro, M.6
Nicolo, C.7
Ambrosino, E.8
Merighi, I.F.9
Musiani, P.10
Forni, G.11
Cavallo, F.12
-
23
-
-
0142244181
-
Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases
-
Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5):2113-2126. doi:10.1016/S0002-9440(10)63568-7 (Pubitemid 37310040)
-
(2003)
American Journal of Pathology
, vol.163
, Issue.5
, pp. 2113-2126
-
-
Lin, E.Y.1
Jones, J.G.2
Li, P.3
Zhu, L.4
Whitney, K.D.5
Muller, W.J.6
Pollard, J.W.7
-
24
-
-
77954538586
-
An autoimmune-mediated strategy for prophylactic breast cancer vaccination
-
doi: 10.1038/nm.2161
-
Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK (2010) An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 16(7):799-803. doi: 10.1038/nm.2161
-
(2010)
Nat Med
, vol.16
, Issue.7
, pp. 799-803
-
-
Jaini, R.1
Kesaraju, P.2
Johnson, J.M.3
Altuntas, C.Z.4
Jane-Wit, D.5
Tuohy, V.K.6
-
25
-
-
40449140821
-
Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors
-
doi:180/1/26126
-
Ding JW, Zhou T, Zeng H, Ma L, Verbeek JS, Yin D, Shen J, Chong AS (2008) Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors. J Immunol 180(1):261-268. doi:180/1/26126
-
(2008)
J Immunol
, vol.180
, Issue.1
, pp. 261-268
-
-
Ding, J.W.1
Zhou, T.2
Zeng, H.3
Ma, L.4
Verbeek, J.S.5
Yin, D.6
Shen, J.7
Chong, A.S.8
-
26
-
-
78650608742
-
FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
-
doi:10.1073/pnas.1014515107
-
Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, Smith P, Ravetch JV (2010) FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci USA 107(45):19396-19401. doi:10.1073/pnas.1014515107
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.45
, pp. 19396-19401
-
-
Nimmerjahn, F.1
Lux, A.2
Albert, H.3
Woigk, M.4
Lehmann, C.5
Dudziak, D.6
Smith, P.7
Ravetch, J.V.8
-
27
-
-
0242432329
-
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
-
DOI 10.1172/JCI200317426
-
Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G (2003) Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 111(8):1161-1170. doi:10.1172/JCI17426 (Pubitemid 36519933)
-
(2003)
Journal of Clinical Investigation
, vol.111
, Issue.8
, pp. 1161-1170
-
-
Curcio, C.1
Di Carlo, E.2
Clynes, R.3
Smyth, M.J.4
Boggio, K.5
Quaglino, E.6
Spadaro, M.7
Colombo, M.P.8
Amici, A.9
Lollini, P.-L.10
Musiani, P.11
Forni, G.12
-
28
-
-
52049120831
-
ErbB2 transgenic mice: A tool for investigation of the immune prevention and treatment of mammary carcinomas
-
Chapter 20:Unit 20 29 21- 20 29-10 doi:10.1002/0471142735.im2009s82
-
Quaglino E, Mastini C, Forni G, Cavallo F (2008) ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol Chapter 20:Unit 20 29 21-20 29-10. doi:10.1002/0471142735.im2009s82
-
(2008)
Curr Protoc Immunol
-
-
Quaglino, E.1
Mastini, C.2
Forni, G.3
Cavallo, F.4
-
29
-
-
79953831715
-
2011: The immune hallmarks of cancer
-
doi:10.1007/s00262-010-0968-0
-
Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL (2011) 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60(3):319-326. doi:10.1007/s00262-010-0968-0
-
(2011)
Cancer Immunol Immunother
, vol.60
, Issue.3
, pp. 319-326
-
-
Cavallo, F.1
De Giovanni, C.2
Nanni, P.3
Forni, G.4
Lollini, P.L.5
-
30
-
-
44249087196
-
Anti-angiogenic active immunotherapy: A new approach to cancer treatment
-
doi:10.1007/s00262-008-0452-2
-
Pan J, Jin P, Yan J, Kabelitz D (2008) Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother 57(8):1105-1114. doi:10.1007/s00262-008-0452-2
-
(2008)
Cancer Immunol Immunother
, vol.57
, Issue.8
, pp. 1105-1114
-
-
Pan, J.1
Jin, P.2
Yan, J.3
Kabelitz, D.4
-
31
-
-
33644603226
-
Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer
-
doi:10.1186/1471-2407-6-16
-
Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE (2006) Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 6:16. doi:10.1186/1471-2407-6-16
-
(2006)
BMC Cancer
, vol.6
, pp. 16
-
-
Jiang, W.G.1
Watkins, G.2
Douglas-Jones, A.3
Holmgren, L.4
Mansel, R.E.5
-
32
-
-
40449086341
-
Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo
-
DOI 10.1096/fj.07-9509com
-
Levchenko T, Veitonmaki N, Lundkvist A, Gerhardt H, Ming Y, Berggren K, Kvanta A, Carlsson R, Holmgren L (2008) Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo. FASEB J 22(3):880-889. doi:10.1096/fj.07-9509com (Pubitemid 351348139)
-
(2008)
FASEB Journal
, vol.22
, Issue.3
, pp. 880-889
-
-
Levchenko, T.1
Veitonmaki, N.2
Lundkvist, A.3
Gerhardt, H.4
Ming, Y.5
Berggren, K.6
Kvanta, A.7
Carlsson, R.8
Holmgren, L.9
-
33
-
-
33745963117
-
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker
-
DOI 10.1200/JCO.2006.06.8080
-
Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24(20):3293-3298. doi:10.1200/JCO.2006.06. 8080 (Pubitemid 46622069)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.20
, pp. 3293-3298
-
-
Hylton, N.1
-
34
-
-
53749092242
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
-
doi:10.1200/JCO.2007.15.5655
-
Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26(28):4572-4578. doi:10.1200/JCO.2007.15.5655
-
(2008)
J Clin Oncol
, vol.26
, Issue.28
, pp. 4572-4578
-
-
Hahn, O.M.1
Yang, C.2
Medved, M.3
Karczmar, G.4
Kistner, E.5
Karrison, T.6
Manchen, E.7
Mitchell, M.8
Ratain, M.J.9
Stadler, W.M.10
-
35
-
-
23844524757
-
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma
-
DOI 10.1158/1078-0432.CCR-04-2655
-
Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F (2005) Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11(16):5827-5832. doi:10.1158/1078-0432.CCR-04-2655 (Pubitemid 41170309)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.16
, pp. 5827-5832
-
-
Marzola, P.1
Degrassi, A.2
Calderan, L.3
Farace, P.4
Nicolato, E.5
Crescimanno, C.6
Sandri, M.7
Giusti, A.8
Pesenti, E.9
Terron, A.10
Sbarbati, A.11
Osculati, F.12
-
36
-
-
83155178515
-
MRI of cells and mice at 1 and 7 Tesla with Gd-targeting agents: When the low field is better!
-
doi:10.1002/cmmi.436
-
Geninatti-Crich S, Szabo I, Alberti D, Longo D, Aime S (2011) MRI of cells and mice at 1 and 7 Tesla with Gd-targeting agents: when the low field is better! Contrast Media Mol Imaging 6(6):421-425. doi:10.1002/cmmi.436
-
(2011)
Contrast Media Mol Imaging
, vol.6
, Issue.6
, pp. 421-425
-
-
Geninatti-Crich, S.1
Szabo, I.2
Alberti, D.3
Longo, D.4
Aime, S.5
-
37
-
-
77955661133
-
Visualizing vascular permeability and lymphatic drainage using labeled serum albumin
-
doi:10.1007/s10456-010-9170-4
-
Vandoorne K, Addadi Y, Neeman M (2010) Visualizing vascular permeability and lymphatic drainage using labeled serum albumin. Angiogenesis 13(2):75-85. doi:10.1007/s10456-010-9170-4
-
(2010)
Angiogenesis
, vol.13
, Issue.2
, pp. 75-85
-
-
Vandoorne, K.1
Addadi, Y.2
Neeman, M.3
-
38
-
-
77952785340
-
Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies
-
doi:10.4049/jimmunol.0903375
-
Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R (2010) Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 184(8): 4170-4177. doi:10.4049/jimmunol.0903375
-
(2010)
J Immunol
, vol.184
, Issue.8
, pp. 4170-4177
-
-
Porzia, A.1
Lanzardo, S.2
Citti, A.3
Cavallo, F.4
Forni, G.5
Santoni, A.6
Galandrini, R.7
Paolini, R.8
-
39
-
-
77955534002
-
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
-
doi:10.1016/j.ccr.2010.06.014
-
Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2):160-170. doi:10.1016/j.ccr.2010.06.014
-
(2010)
Cancer Cell
, vol.18
, Issue.2
, pp. 160-170
-
-
Park, S.1
Jiang, Z.2
Mortenson, E.D.3
Deng, L.4
Radkevich-Brown, O.5
Yang, X.6
Sattar, H.7
Wang, Y.8
Brown, N.K.9
Greene, M.10
Liu, Y.11
Tang, J.12
Wang, S.13
Fu, Y.X.14
-
40
-
-
0043245914
-
Synergy between tumor immunotherapy and antiangiogenic therapy
-
DOI 10.1182/blood-2002-12-3738
-
Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102(3):964-971. doi:10.1182/blood-2002-12-3738 (Pubitemid 36917791)
-
(2003)
Blood
, vol.102
, Issue.3
, pp. 964-971
-
-
Nair, S.1
Boczkowski, D.2
Moeller, B.3
Dewhirst, M.4
Vieweg, J.5
Gilboa, E.6
-
41
-
-
70350655979
-
VEGF as an inhibitor of tumor vessel maturation: Implications for cancer therapy
-
doi:10.1517/14712590903208883
-
Greenberg JI, Cheresh DA (2009) VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 9(11):1347-1356. doi:10.1517/14712590903208883
-
(2009)
Expert Opin Biol Ther
, vol.9
, Issue.11
, pp. 1347-1356
-
-
Greenberg, J.I.1
Cheresh, D.A.2
-
42
-
-
79960096827
-
Normalization of the vasculature for treatment of cancer and other diseases
-
doi: 10.1152/physrev.00038.2010
-
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071-1121. doi: 10.1152/physrev.00038.2010
-
(2011)
Physiol Rev
, vol.91
, Issue.3
, pp. 1071-1121
-
-
Goel, S.1
Duda, D.G.2
Xu, L.3
Munn, L.L.4
Boucher, Y.5
Fukumura, D.6
Jain, R.K.7
|